Brief: Gimv Announces Investment To Support Clinical Developement Of Asthma Treatment

Gimv NV

30/11/2020 07:14

Nov 30 (Reuters) - GIMV INVESTERINGSMAATSCHAPPIJ VOOR
VLANDEREN NV  GIMV.BR :
    * IS FOUNDING INVESTOR OF KINASET THERAPEUTICS IN A USD 40M
SERIES
A ROUND
    * A PHASE 1/1B CLINICAL TRIAL IN HEALTHY VOLUNTEERS AND
PATIENTS
IS POISED TO BEGIN IN FIRST HALF OF 2021
    * INVESTS TO SUPPORT CLINICAL DEVELOPMENT OF KN-002, A NOVEL
DRY
POWDER INHALABLE PAN-JAK INHIBITOR, FOR THE TREATMENT OF
EOSINOPHILIC AND NON-EOSINOPHILIC SEVERE ASTHMA

Source text for Eikon:  ID:nNDLbTFzVn 
Further company coverage:  GIMV.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))